Current Application Status and Suitable Population Analysis of Oocyte Activation (OA) Technology in Georgia

Clinical Decision Scenario: When Fertilization Failure Occurs in an ICSI Cycle

In reproductive medicine outpatient clinics, when a couple presents with a fertilization report from a previous ICSI cycle showing a fertilization rate of only 10% or complete fertilization failure, the attending physician must quickly determine where the problem lies. Is it that the sperm failed to activate the egg, or does the egg itself have an activation disorder, or both? This judgment directly determines whether to proceed with oocyte activation technology (OA) or to consider other options such as donor sperm or donor eggs. In Georgia, some centers with assisted reproductive technology qualifications have incorporated OA into their clinical pathways, but controlling the indications is key.

Direct Answer on Oocyte Activation Technology (OA)

Oocyte activation technology (OA) is a technique that artificially mimics physiological calcium oscillations to activate the oocyte, thereby completing the fertilization process. In Georgia, centers with assisted reproductive technology qualifications, such as some reproductive institutions in Tbilisi and Batumi, can offer this technology. The core value of OA lies in resolving fertilization failure caused by defects in the sperm's PLCζ protein or abnormal oocyte activation response. It is important to clarify that OA is not suitable for all cases of fertilization failure; its effectiveness is highly dependent on the specific cause of the failure. For patients definitively diagnosed with oocyte activation deficiency, OA can increase the fertilization rate from 0-30% to 50%-70%.

Why Fertilization Fails: The Mechanism of Activation Deficiency

Oocyte activation failure is one of the main causes of fertilization failure after ICSI. In the normal physiological process, after the sperm enters the egg, the PLCζ protein released from its acrosome triggers repeated oscillations in calcium ion concentration within the egg. This calcium signaling is key to initiating egg activation, completing meiosis, and forming male and female pronuclei. When the sperm's PLCζ protein expression is insufficient or functionally abnormal, or when there is a defect in the egg's calcium signaling pathway, fertilization failure or a low fertilization rate can occur. Clinical data shows that approximately 40%-60% of complete fertilization failure cases after ICSI are related to oocyte activation deficiency. In Georgia, reproductive centers typically recommend sperm PLCζ testing and oocyte activation testing for patients with recurrent fertilization failure to identify the cause. Additionally, insufficient oocyte maturity or abnormal cytoplasmic maturation can also lead to activation failure, and the improvement effect of OA in such cases is limited.

Reproductive Specialist's Perspective: Precise Positioning of OA Technology

From a professional reproductive medicine perspective, OA technology is an example of the application of precision medicine in the field of assisted reproduction. It targets the specific link of "activation deficiency" in the chain of fertilization failure. In clinical practice in Georgia, the application of OA technology must strictly adhere to the following indications:

• Complete fertilization failure or a fertilization rate below 30% in a previous ICSI cycle
• Confirmed defect in sperm PLCζ (positive result from immunofluorescence or Western blot)
• Oocyte activation test indicating an abnormal activation response, but with acceptable basic oocyte quality
• Female age typically not exceeding 38 years, with normal ovarian reserve (AMH ≥ 1.1 ng/mL, AFC ≥ 6)
• Other clear causes such as chromosomal abnormalities or extremely high sperm DNA fragmentation have been ruled out

When making a decision, the physician will comprehensively evaluate factors such as the patient's etiology, age, ovarian reserve, and history of previous cycles. It is not recommended to blindly use OA technology without a clear diagnosis, as this may delay the opportunity for other effective treatment options.

Easily Overlooked Details

When evaluating and using OA technology, the following details are often overlooked:

Feasibility of Sperm PLCζ Testing

Some reproductive centers in Georgia may not have the laboratory conditions for PLCζ testing and may need to send samples to specialized facilities, which increases time and cost. It is recommended to confirm with the center whether they offer this test or an external referral service before treatment.

Differences in Activation Methods

Common activation methods include calcium ionophores (e.g., ionomycin) and electrical activation. Different methods have varying stimulation intensities and effects on the egg. The embryologist's experience and operating habits can influence the final outcome. Some centers in Georgia use electrical activation, while calcium ionophores are more common domestically. There is no significant difference in clinical pregnancy rates between the two methods.

Limitations of the Oocyte Activation Test

This test cannot fully simulate the in vivo activation process and has a certain rate of false negatives and false positives. Even if the activation test result is normal, fertilization failure can still occur in a clinical ICSI cycle.

Developmental Potential of Embryos After OA

Although OA can improve the fertilization rate, the quality of the resulting embryos still depends on the basic quality of the sperm and egg. OA cannot improve embryonic developmental abnormalities or chromosomal aneuploidy caused by poor gamete quality.

Risk of Polyspermy

Artificial activation may increase the incidence of 3PN (tripronuclear) fertilization, typically around 5%-10%, which can reduce the number of transferable embryos. Choosing an experienced embryologist can help lower this risk.

Common Pitfalls

Based on clinical observations, the following misconceptions are common in patient decision-making:

Actual Procedure for OA Technology in Georgia

The standard operating procedure for OA technology in Georgian reproductive centers is as follows:

Phase 1: Comprehensive Etiological Evaluation

• Sperm PLCζ protein detection (immunofluorescence or Western blot)
• Oocyte activation test (using mouse oocytes or the patient's own oocytes)
• Sperm DNA fragmentation test (SCD or TUNEL method)
• Karyotype analysis of both partners
• Female ovarian reserve assessment (AMH, AFC, FSH)

Phase 2: Informed Consent

Inform the patient about the principles of OA technology, expected success rates, potential risks (polyspermy, egg damage, embryonic developmental abnormalities, etc.), and alternative options (donor sperm, donor eggs, embryo donation, etc.).

Phase 3: Ovarian Stimulation and Egg Retrieval

Use a standard ovarian stimulation protocol (long protocol, antagonist protocol, etc.). Assess oocyte maturity (MII oocyte rate) after retrieval. The ideal MII oocyte proportion should be no less than 80%.

Phase 4: ICSI Procedure

Select morphologically normal mature oocytes for ICSI. After sperm injection, observe whether the oocyte shows signs of activation. For patients expected to have activation difficulties, prepare for the activation procedure immediately after ICSI.

Phase 5: Artificial Activation

Use a calcium ionophore (ionomycin) or an electrical activation device for activation. Immediately after activation, observe whether the oocyte exhibits calcium oscillations. Controlling the timing and duration of activation is a technical key point.

Phase 6: Fertilization Observation and Embryo Culture

Observe pronucleus formation 16-18 hours after activation. Record the fertilization rate and polyspermy rate. Successfully fertilized embryos continue to be cultured to the cleavage or blastocyst stage, monitoring developmental speed and morphological grading.

Phase 7: Embryo Transfer or Cryopreservation

Select high-quality embryos for fresh transfer or vitrification cryopreservation. Provide routine luteal phase support after transfer.

Comparison of Suitable and Unsuitable Populations

Frequently Asked Questions

1. Is OA technology safe? Does it affect the embryo?

OA technology has been used in clinical assisted reproduction for many years and has a good overall safety profile. The artificial activation process is an additional stimulation to the egg and may increase the rate of polyspermy (approximately 5%-10%). In rare cases, it can cause egg damage. Current research shows that the pregnancy outcomes after transferring embryos obtained through OA are not significantly different from those of conventional ICSI embryos. In Georgia, reputable reproductive centers provide thorough informed consent before using OA and strictly control the activation conditions during the procedure.

2. What is the cost of OA in Georgia?

In Georgia, OA technology, as an add-on to ICSI, typically costs an additional $2,000-$4,000 USD, depending on the activation method used (calcium ionophore or electrical activation), laboratory conditions, and whether it includes supporting tests like PLCζ detection. The total cycle cost (including ovarian stimulation, egg retrieval, ICSI, OA, embryo culture, and transfer) is approximately between $8,000 and $15,000 USD. Pricing varies between different reproductive centers, so it is advisable to obtain a detailed breakdown in advance.

3. How much does OA technology improve the success rate?

For patients definitively diagnosed with oocyte activation deficiency, OA technology can increase the fertilization rate from 0-30% to 50%-70%. However, the embryo implantation rate and clinical pregnancy rate after successful fertilization are not significantly different from the conventional ICSI population, being approximately 40%-50% (depending on patient age and embryo quality). It is important to emphasize that OA cannot improve subsequent embryonic developmental failure due to poor gamete quality.

4. How do I know if I need OA?

Consider an OA evaluation in the following situations: ① Complete fertilization failure in a previous ICSI cycle; ② Fertilization rate consistently below 30% across multiple ICSI cycles; ③ Known mutation in the sperm PLCζ gene; ④ Oocyte activation test indicates abnormal activation. It is recommended to undergo a complete evaluation at a reproductive center in Georgia with the appropriate testing capabilities, and not to make a decision based on the result of just one cycle.

5. Is there a difference between OA technology in Georgia and domestically?

The main differences are: ① Some centers in Georgia use electrical activation, while calcium ionophores are more common domestically; ② Some tests in Georgia (like PLCζ testing) may need to be sent out, whereas some domestic centers can perform them in-house; ③ There are slight differences in the selection of indications and operational details between the two countries, but the technical principles and core operating standards are consistent. When choosing a center, focus on its experience with OA procedures rather than its geographical location.

Risk Reminder

While oocyte activation technology (OA) provides an important solution for patients with fertilization failure, it is not without limitations and risks. The artificial activation process can cause abnormal egg activation, polyspermy, and embryonic developmental arrest. Furthermore, the long-term effects of OA technology on embryos are still under investigation, and large-sample long-term follow-up data are currently lacking. Before deciding to use OA, it is essential to complete a comprehensive etiological evaluation at a reproductive center with the appropriate technical capabilities and to fully understand the technology's indications, expected benefits, and potential risks. Choosing a reputable institution with experience in OA technology and having the procedure performed by a professional embryologist are key to ensuring safety and effectiveness. At the same time, it is advisable to be mentally and financially prepared for the possibility of needing multiple cycle attempts.